Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05799911
Other study ID # FTK_2023_11
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 11, 2023
Est. completion date May 31, 2023

Study information

Verified date May 2023
Source Palacky University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this randomized, double-blind, placebo-controlled crossover trial is to evaluate the effect of hydrogen-rich water consumption on performance, recovery, psychological and biochemical outcomes in elite Czech fin-swimmers.


Description:

Twelve Czech national and international-level fin-swimmers participate in this trial. Participants take molecular hydrogen via drinking hydrogen-rich water (HRW) or placebo three days before (1260 ml/day) and during testing day (2520 ml). All participants participate in two testing session and receive HRW and placebo in random order. Each session includes two training units in a 25-m indoor swimming pool and a 24-hour monitored recovery. The first training unit takes place in the morning between 9 and 11 AM and includes three high intensity interval sets. The afternoon training unit includes a continuous 400-m competitive performance. The washout period between testing sessions is 7 days. The variables assessed are as follows: swimming times, heart rate variability, lower limb explosive strength, rating of perceived exertion, subjective perceived muscle soreness, creatine kinase, blood lactate, and protein carbonyls. Statistical analysis is based on analysis of variance for repeated measures with factors: water (HRW and placebo), time, and interaction. Fisher's post-hoc tests is used for pairwise comparisons. The significance level is set at 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date May 31, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 30 Years
Eligibility Inclusion Criteria: - Junior or adult Czech fin-swimming representative. - Medical eligibility for competitive sport. - Good health condition. - Signed informed consent. Exclusion Criteria: - Acute health problems. - Not following instructions (free of any supplements three weeks before experiment, free of any medicaments, no caffeine at least 24 hours before experiment). - Menstruation in testing session.

Study Design


Intervention

Dietary Supplement:
Hydrogen rich water
Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
Placebo
Tap water with molecular hydrogen concentration 0.0 ppm.

Locations

Country Name City State
Czechia Palacky University, Faculty of Physical Culture Olomouc

Sponsors (1)

Lead Sponsor Collaborator
Palacky University

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Swimming time for 400 m Swimming time is recorded according to swimming and fin-swimming rules. Swimming time is measured by two qualified timekeepers. The longer time is the official time. Change between values before and after 7 days of crossover.
Secondary Swimming time for 50 m Swimming time is recorded according to swimming and fin-swimming rules. Swimming time is measured by three qualified timekeepers. If two of the three watches record the same time and the third disagrees, the two identical times is the official time. If all three watches disagree, the watch recording the intermediate time is the official time. The 50-m swimming is repeated in 3 sets and 4 rounds, representing 12 measured times. Change between values before and after 7 days of crossover.
Secondary Heart rate variability To determine heart rate variability variables, the ECG signal is measured at a sampling frequency of 1000 Hz using DiANS PF8 (DIMEA Group, Olomouc, Czech Republic). ECG sampling is performed during an orthoclinostatic maneuver (supine-standing-supine) in calm room without any acoustic or visual disturbances. Time domain variables (RMSSD and SDNN) and frequency domain variables (high and low frequency power) are calculated from the ECG. Variables are measured before and after the first training unit, before and after the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
Secondary Lower limb explosive strength The subject performs 3 single maximum effort countermovement jumps with 30 seconds of rest between each jump. The starting position for the jump is an upright posture with the hands placed on the hips. Vertical ground reaction force is measured on 2 parallel force platforms (AMTI OR6-7-1000, Advanced Mechanical Technology, Watertown, USA) with a sampling frequency of 1000 Hz. The jump height is calculated from the measured force-time curve and the average of three jumps is considered for subsequent analysis. The jump height is measured before and after the first training unit, before and after the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
Secondary Rating of perceived exertion The subject is asked to score subjective rating of perceived exertion using the scale developed by Borg. All subjects are familiar with the Borg scale before testing. We use modified scale ranged from 1 (no exertion at all) to 10 (maximum exertion). The rating is scored immediately after each set of 50-m swimming and after 400-m swimming. Change between values before and after 7 days of crossover.
Secondary Subjective perceived muscle soreness Visual analogue scale (VAS) is used to assess lower limb muscle soreness. The VAS is a horizontal 100 mm length line, marked with 0, indicating "no pain" and 100 indicating the "worst imaginable pain". The VAS is assessed before and after the first training unit, before and after the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
Secondary Creatine kinase Creatine kinase is evaluated based on blood samples taken from fingertip. An alcohol wipe is used to clean fingertip and the skin is punctured with lancet. First drop is wiped away and the second drop is used. A Reflotron applicator with a 32 µL disposable pipette tip is used to extract a 32 µL sample of blood and place it on a creatine kinase assay strip (Reflotron CK strips, Roche Diagnostics, Rotkreuz, Switzerland). The blood sample is analyzed using a spectrophotometer (Reflotron Plus, Roche Diagnostics, Rotkreuz, Switzerland) to set plasma creatine kinase concentration.The creatine kinase is evaluated before the first training unit, before the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
Secondary Blood lactate Blood lactate concentration is evaluated based on blood samples taken from fingertip. An alcohol wipe is used to clean fingertip and the skin will be punctured with lancet. First drop is wiped away and the second drop is be used. For lactate sampling the analyzer Lactate Scout+ (EKF Diagnostics, Cardiff, United Kingdom) is used. The blood lactate is evaluated before the first training unit, after each set of 50-m swimming, after swim-up, before and after the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
Secondary Protein carbonyls Protein carbonyls are detected from vein blood sample which is taken from the inside of the elbow by a healthcare specialist. The blood is taken into heparinized vacuum tubes. These is then centrifuged at 1000 g. Subsequently, the blood plasma is separated into cryotubes and frozen at -80 °C until biochemical analysis. Protein carbonyls concentration is measured by ELISA method in accordance with the manufacturer's manual (Protein carbonyl content assay kit, Sigma-Aldrich, Saint Louis, USA). The protein carbonyls is analyzed before the first training unit, before the second training unit, morning and evening of the following day. Change between values before and after 7 days of crossover.
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04136821 - The Long-term Effects of Oceanix™ on Resistance Training Adaptations N/A
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Completed NCT03358524 - Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia Phase 4
Recruiting NCT05327348 - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery Phase 3
Completed NCT03288623 - The Effects of Dark Chocolate Implementation in Elite Athletes N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Enrolling by invitation NCT03030456 - Whole Body Vibrations on Functional Capacity, Muscular Strength, and Biochemical Profile in Elders N/A
Not yet recruiting NCT02202239 - Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients Phase 4
Completed NCT02256254 - SIMOX - Induction of Oxidative Stress Phase 2
Recruiting NCT02048592 - Impact of Immunonutrition on the Patients With Cystic Fibrosis Phase 4
Completed NCT01942460 - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients Phase 4
Completed NCT02463318 - The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects N/A
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Completed NCT02177383 - Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance N/A
Completed NCT00845130 - Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes N/A
Completed NCT00607893 - Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea N/A
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4